Qatar’s Ministry of Public Health (MOPH) has issued a circular explicitly prohibiting the handling, distribution, use, and promotion of unlicensed peptide products, with immediate effect. Circular No. PDC/2026/31, dated August 25, 2026, was issued by the MOPH’s Pharmacy and Drug Control Department and applies to every peptide product placed on the Qatari market without a valid MOPH marketing authorisation.
The prohibition reaches across the full pharmaceutical supply chain — from marketing authorisation holders and importers to distributors and pharmacies. It also names weight-loss and cosmetic clinics explicitly, signaling that the MOPH is targeting the clinical settings where unlicensed peptides have proliferated alongside the global GLP-1 and peptide therapeutics boom.
The move represents a notable regulatory development for the Gulf region, where peptide use has grown in recent years alongside the global GLP-1 boom. It may also carry implications for international suppliers and telehealth platforms with exposure to Middle Eastern markets.
What happened
On August 25, 2026, the MOPH’s Pharmacy and Drug Control Department issued Circular PDC/2026/31, converting a standing licensing expectation into a binding prohibition with immediate effect. The circular prohibits four specific activities — handling, distribution, use, and promotion — related to any peptide product that lacks a valid MOPH marketing authorisation.
The instrument names several categories of affected entities:
- Pharmaceutical marketing authorisation holders
- Importers and distributors
- Pharmacies
- Weight-loss and cosmetic clinics
By naming clinics directly, the circular extends beyond the traditional pharmaceutical supply chain to encompass the clinical environments where unlicensed peptides may be administered, prescribed, or promoted to patients.
Why it matters
One industry report describes this as the first explicitly named prohibition from a Gulf Cooperation Council (GCC) regulatory authority to target unlicensed peptides directly. This characterization has not been independently confirmed as a regional first.
What is clear is that the circular establishes a harder enforcement line than prior guidance. Qatar’s action may signal broader regulatory tightening across Middle Eastern markets where peptide use has grown alongside the global expansion of GLP-1 therapeutics. Neighboring regulators in Saudi Arabia, the United Arab Emirates, Bahrain, and Oman could observe Qatar’s approach as they assess their own peptide regulatory frameworks.
The prohibition also carries potential implications beyond Qatar’s borders. International peptide suppliers with Gulf market exposure may see ripple effects, and telehealth platforms serving Middle Eastern patients could also be affected if similar measures spread across the GCC.
What to watch next
- Whether neighboring GCC regulators issue comparable prohibitions or guidance on unlicensed peptides
- How Qatari authorities enforce the circular, particularly against weight-loss and cosmetic clinics
- Whether international peptide suppliers adjust their Gulf market strategies in response
- Any further MOPH guidance clarifying the scope of “handling” and “promotion” under the circular
Sources
Obsidian Regulatory Intelligence
Industry information only. Not medical or legal advice.
